Taken together our findings indicate that at least in immunogenic tumors, Compound 182 may be efficacious not only by inhibiting PTP1B/PTPN2 in T cells to drive T cell activation, expansion and cytotoxicity, but also by promoting T cell-mediated inflammation and consequent STAT-1 signaling in tumor cells to exacerbate T cell recruitment and anti-tumor immunity. This evidence concerns the gene STAT1 and neoplasm.